Suven Life Sciences(530239)

suven life (530239)
recommeded @34
target -50 in few months




The company made this announcement during the trading hours on Tuesday, 27 November 2007.

Meanwhile, BSE Sensex was up 106.55 points or 0.56% to 19,234.28.

On BSE 19,200 shares were traded in the counter. The scrip had an average daily volume of 73,969 shares in the past one quarter.

The stock hit a high of Rs 35 and a low of Rs 34.10 so far during the day. The stock had a 52-week high of Rs 46.90 on 20 August 2007 and a 52-week low of Rs 22.90 on 1 December 2006.

The small-cap scrip had underperformed the market over the past one month till 26 November 2007, declining 6.91% compared to the Sensex’s return of 0.02%. It had also underperformed the market in the past one quarter, declining 11.73% compared to Sensex’s rise of 33.43%.

The company’s current equity is Rs 11.56 crore. Face value per share is Rs 1.

The current price of Rs 34.90 discounts Q2 September 2007 annualized EPS of Rs 0.40 by a PE multiple of 87.25.

Suven has three European Patents granted until now and all of them have been validated in all the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland.

On 31 October 2007, Suven Life Sciences announced that two of its new chemical entities for the treatment of disorders associated with neurodegenerative diseases were granted patents in Australia and New Zealand and these patents are valid until 2022.

On 23 October 2007, Suven Life Sciences announced that the Indian Patent Office had granted three product patents to three new chemical entities (NCEs) of the company for the treatment of disorders associated with neurodegenerative diseases and theses patents are valid until 2022.

Suven Life Sciences’ net profit declined 53.4% to Rs 1.16 crore on 0.1% fall in net sales to Rs 27.84 crore in Q2 September 2007 over Q2 September 2006.

Suven Life Sciences’ principal activity is to design, manufacture and the supply of bulk active, drug intermediates and fine chemicals to the life science industry. The company mainly operates in the USA, Europe, Asia and India.